Molecular profiling in MPN: who should have it and why?

Hematology Am Soc Hematol Educ Program

Cancer and Haematology Centre, Department of Clinical Haematology, The Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Published: December 2024

Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are a group of blood cancers that result from somatic mutations in hematopoietic stem cells, causing constitutive activation of JAK-STAT signaling pathways with consequent overproduction of 1 or more myeloid lineages. The initiating event in MPN pathogenesis is a genetic mutation, and consequently molecular profiling is central to the diagnosis, risk stratification, and, increasingly, monitoring of therapy response in persons with MPN. In this review we summarize current approaches to molecular profiling of classical MPNs (essential thrombocythemia, polycythemia vera, and myelofibrosis), using illustrative clinical case histories to demonstrate how genetic analysis is already fully integrated into MPN diagnostic classification and prognostic risk stratification. Molecular profiling can also be used in MPN to measure response to therapy both in clinical trials and increasingly in routine clinical practice. Taking a forward look, we discuss how molecular profiling in MPN might be used in the future to select specific molecularly targeted therapies and the role of additional genetic methodologies beyond mutation analysis.

Download full-text PDF

Source
http://dx.doi.org/10.1182/hematology.2024000576DOI Listing

Publication Analysis

Top Keywords

molecular profiling
20
profiling mpn
12
risk stratification
8
mpn
6
molecular
5
mpn why?
4
why? philadelphia
4
philadelphia chromosome-negative
4
chromosome-negative myeloproliferative
4
myeloproliferative neoplasms
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!